PI-CARDIA
Pi-Cardia is a medical device start-up company developing a novel low profile catheter for the treatment of aortic stenosis. The company's proprietary technology is based on delivering mechanical impact for creating fractures in valve calcifications, without injuring the surrounding soft tissue. This treatment, which only takes several seconds, is intended to increase the valve effective orifice area without the need to replace the valve.
PI-CARDIA
Social Links:
Industry:
Health Care Medical Medical Device
Founded:
2009-01-01
Address:
Herzliya, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.pi-cardia.net
Total Employee:
11+
Status:
Active
Contact:
+97297885599
Email Addresses:
[email protected]
Total Funding:
37 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Amazon
Current Advisors List
Current Employees Featured
Founder
Investors List
Sofinnova Partners
Sofinnova Partners investment in Venture Round - Pi-Cardia
Jacques R. Seguin
Jacques R. Seguin investment in Venture Round - Pi-Cardia
Innogest Capital
Innogest Capital investment in Series C - Pi-Cardia
Atlante Ventures
Atlante Ventures investment in Series C - Pi-Cardia
Clal Biotechnology Industries
Clal Biotechnology Industries investment in Series C - Pi-Cardia
Atlante Ventures
Atlante Ventures investment in Series C - Pi-Cardia
Accelmed
Accelmed investment in Series B - Pi-Cardia
Anges Quebec
Anges Quebec investment in Seed Round - Pi-Cardia
Official Site Inspections
http://www.pi-cardia.net Semrush global rank: 9.37 M Semrush visits lastest month: 169
- Host name: 147.62.236.23.bc.googleusercontent.com
- IP address: 23.236.62.147
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Pi-Cardia"
Pi-Cardia - Crunchbase Company Profile & Funding
Pi-Cardia is a medical device start-up company developing a novel low profile catheter for the treatment of aortic stenosis. The company's proprietary technology is based on delivering mechanical impact for creating fractures in …See details»
About | Pi Cardia - Current
Pi-Cardia is a global leader in the development of a unique portfolio of non-implant, catheter-based, leaflet modification solutions for treating heart valves. The ShortCutâ„¢ device is a safe, simple and effective way to split valve …See details»
Pi-Cardia Company Profile 2024: Valuation, Funding & Investors
Pi-Cardia General Information Description. Developer of medical catheter technological device designed to offer treatment of aortic stenosis. The company's device is a trans-femoral …See details»
Pi-Cardia Receives FDA Market Clearance for ShortCutâ„¢ - tctmd.com
Oct 1, 2024 REHOVOT, Israel--(BUSINESS WIRE)--Pi-Cardia Ltd., a global leader in the development of leaflet modification solutions for treating heart valves, announced today that …See details»
Pi-Cardia Company Profile - Office Locations, Competitors ... - Craft
Pi-Cardia has 5 employees across 2 locations and $37 m in total funding,. See insights on Pi-Cardia including office locations, competitors, revenue, financials, executives, subsidiaries and …See details»
Pi-Cardia Hires Gary Gratson to Lead Global Commercialization
Dec 11, 2023 REHOVOT, Israel — Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced …See details»
Pi-Cardia - Overview, News & Similar companies | ZoomInfo.com
Who is Pi-Cardia. Pi-Cardia is a global leader in the development of unique non-implant-based solutions for treating valve calcification. Pi-Cardia's lead product, t he Leaflex Performer …See details»
Pi-Cardia Receives FDA Market Clearance for ShortCutâ„¢
Sep 30, 2024 REHOVOT, Israel--(BUSINESS WIRE)--Pi-Cardia Ltd., a global leader in the development of leaflet modification solutions for treating heart valves, announced today that …See details»
Pi-Cardia Hires Gary Gratson to Lead Global Commercialization
REHOVOT, Israel, December 11, 2023--Pi-Cardia, a leader in non-implant solutions for heart valves treatment , announces Gary Gratson to lead commercial operations for ShortCutâ„¢ device.See details»
Pi-Cardia hires Gary Gratson to lead global commercialization
Dec 11, 2023 Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced today it hired Gary Gratson …See details»
Pi-Cardia Successfully Treats First Patients with ShortCutâ„¢ Device
Jan 7, 2021 Pi-Cardia is a global leader in the development of unique non-implant-based solutions for treating heart valves. Pi-Cardia’s lead product, the Leaflexâ„¢ device, is easily …See details»
ShortCut Catheter | Pi Cardia
ShortCut Catheter. Intended to enable coronary access and prevent coronary obstruction during TAVI. Complete control over positioning and leaflet splitting location. Designed for safe, simple …See details»
Pi-Cardia receives FDA Breakthrough Device Designation for
Jan 22, 2024 Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced today it received …See details»
Pi-Cardia Closes a $27 Million Financing led by Sofinnova Partners …
Apr 20, 2020 Pi-Cardia Ltd., a global leader in the development of non-implant catheter-based solutions for treating heart valve calcification, announced today it has closed a $27 million …See details»
First US Patient Successfully Treated with ShortCut
REHOVOT, ISRAEL / December 21, 2022 / Pi-Cardia Ltd., focused on the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced that …See details»
Pi-Cardia's ShortCut Catheter Gets FDA Breakthrough Designation ...
Oct 31, 2024 ShortCut is the first dedicated leaflet modification device to enable TAVR in patients at risk of coronary obstruction. The US Food and Drug Administration (FDA) granted …See details»
Pi-Cardia appoints Gary Gratson to lead commercialisation of …
Dec 12, 2023 Pi-Cardia has appointed Gary Gratson to lead commercial operations for ShortCut, its dedicated leaflet modification device to enable transcatheter aortic valve …See details»
First US Patient Successfully Treated with ShortCut(TM)
Dec 19, 2022 First Dedicated Leaflet Splitting Device To Facilitate Valve-in-Valve Procedures. REHOVOT, ISRAEL / ACCESSWIRE / December 19, 2022 / Pi-Cardia Ltd., a global leader in …See details»
First dedicated transcatheter leaflet splitting device: the ShortCut ...
The ShortCut (Pi-Cardia) device is designed to split bioprosthetic aortic valve leaflets in patients undergoing ViV-TAVR procedures who are at risk for TAVR-induced coronary artery …See details»